Immune safety challenges facing the preclinical assessment and clinical progression of cell therapies
Stephanie M Bates1, Kelly V Evans1, Louise Delsing2
1Safety Innovation, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Abstract:
The promise of curative outcomes for life-limiting diseases using cell therapies is starting to become a reality, not only for patients with end-stage cancer, but also increasingly for regenerative therapies, including dentistry, ocular, neurodegenerative, and cardiac diseases. The introduction of often genetically modified cells into a patient can come with an extensive range of safety considerations. From an immune perspective, cell-based therapies carry inherent consequences and consideration of factors, such as the cell source (donor-derived autologous cells versus allogeneic cells), the intrinsic cellular nature of the therapy, and engineering/manufacturing methods, all of which influence the likelihood of inducing unwanted immune responses. Here, we provide an overview of the potential immune safety risks associated with cell therapies and explore possible mitigation approaches.
Insights
Cell therapies offer curative potential for serious diseases, but immune responses pose safety risks. This overview examines these risks and strategies to mitigate them for safer cell-based treatments.
Area of Science:
- Immunology
- Regenerative Medicine
- Biotechnology
Background:
- Cell therapies are emerging as a promising treatment for life-limiting conditions, including cancer and degenerative diseases.
- The introduction of cells, especially genetically modified ones, necessitates careful safety evaluations.
- Immune responses are a significant concern in cell therapy efficacy and safety.
Purpose of the Study:
- To provide an overview of potential immune safety risks associated with cell therapies.
- To explore various approaches for mitigating these immune-related risks.
- To highlight the importance of considering immune responses in cell therapy development.
Main Methods:
- Literature review of immune responses in cell therapy.
- Analysis of factors influencing immunogenicity (cell source, therapy type, manufacturing).
- Exploration of immune mitigation strategies.
Main Results:
- Cell source (autologous vs. allogeneic), cell type, and manufacturing processes significantly impact immune risk.
- Unwanted immune responses can compromise cell therapy efficacy and patient safety.
- Various strategies exist to manage and reduce immune reactions.
Conclusions:
- Understanding and addressing immune safety is critical for the successful clinical application of cell therapies.
- Proactive mitigation of immune risks is essential for advancing regenerative medicine and cell-based treatments.
- Further research into immune modulation will enhance the therapeutic potential of cell-based interventions.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
